I Marcil1, R S Stern. 1. Department of Dermatology, Beth Israel Deaconess Medical Center-East Campus, 330 Brookline Ave, Boston, MA 02215, USA.
Abstract
OBJECTIVE: To assess the risk of developing a basal cell carcinoma (BCC), and/or a squamous cell carcinoma (SCC), and/or Bowen disease (SCC in situ) after a nonmelanoma skin cancer (NMSC) of a specific type. DATA SOURCES: Four electronic databases were searched from January 1, 1966, to October 21, 1999. STUDY SELECTION: We included all studies published in English, identified by standard search strategies, that provided original data quantifying the risk of an NMSC among persons with a previous NMSC. DATA EXTRACTION: For each study and separate histological type of index skin tumor and subsequent skin tumor (SCC, BCC, NMSC, or Bowen disease), we determined the 3-year cumulative risk and the incidence rate of second tumors per 100 000 person-years. In cases where more than 1 study was assessing the risk of one specific tumor type after another, we undertook a formal meta-analysis. We compared the incidence of a subsequent SCC after an index SCC and of a subsequent BCC after an index BCC with the incidence of the first occurrence of such tumors in the comparable general population. DATA SYNTHESIS: We identified and reviewed 17 studies that included data for 26 tumor combinations. Overall, the 3-year cumulative risk of a subsequent SCC after an index SCC is 18%, at least a 10-fold increase in incidence compared with the incidence of first tumors in a comparable general population. For BCCs, the 3-year cumulative risk is 44%, also at least a 10-fold increase in incidence compared with the rate in a comparable general population. The risk of developing a BCC in patients with a prior SCC is about equal to that risk among persons with a prior BCC, but the risk of developing an SCC in patients with a prior BCC is low (6%). CONCLUSIONS: Although these studies vary in their study type, location, and biases, their results are consistent. The risk of developing a subsequent skin cancer of a specific type depends on the type of prior NMSC and number of prior skin tumors of that type. Based on these findings, follow-up strategies for patients with BCC and SCC are suggested.
OBJECTIVE: To assess the risk of developing a basal cell carcinoma (BCC), and/or a squamous cell carcinoma (SCC), and/or Bowen disease (SCC in situ) after a nonmelanoma skin cancer (NMSC) of a specific type. DATA SOURCES: Four electronic databases were searched from January 1, 1966, to October 21, 1999. STUDY SELECTION: We included all studies published in English, identified by standard search strategies, that provided original data quantifying the risk of an NMSC among persons with a previous NMSC. DATA EXTRACTION: For each study and separate histological type of index skin tumor and subsequent skin tumor (SCC, BCC, NMSC, or Bowen disease), we determined the 3-year cumulative risk and the incidence rate of second tumors per 100 000 person-years. In cases where more than 1 study was assessing the risk of one specific tumor type after another, we undertook a formal meta-analysis. We compared the incidence of a subsequent SCC after an index SCC and of a subsequent BCC after an index BCC with the incidence of the first occurrence of such tumors in the comparable general population. DATA SYNTHESIS: We identified and reviewed 17 studies that included data for 26 tumor combinations. Overall, the 3-year cumulative risk of a subsequent SCC after an index SCC is 18%, at least a 10-fold increase in incidence compared with the incidence of first tumors in a comparable general population. For BCCs, the 3-year cumulative risk is 44%, also at least a 10-fold increase in incidence compared with the rate in a comparable general population. The risk of developing a BCC in patients with a prior SCC is about equal to that risk among persons with a prior BCC, but the risk of developing an SCC in patients with a prior BCC is low (6%). CONCLUSIONS: Although these studies vary in their study type, location, and biases, their results are consistent. The risk of developing a subsequent skin cancer of a specific type depends on the type of prior NMSC and number of prior skin tumors of that type. Based on these findings, follow-up strategies for patients with BCC and SCC are suggested.
Authors: Christopher P Fagundes; Ronald Glaser; Sheri L Johnson; Rebecca R Andridge; Eric V Yang; Michael P Di Gregorio; Min Chen; David R Lambert; Scott D Jewell; Mark A Bechtel; Dean W Hearne; Joel B Herron; Janice K Kiecolt-Glaser Journal: Arch Gen Psychiatry Date: 2012-06
Authors: Joanne M Jeter; Clara Curiel-Lewandrowski; Steven P Stratton; Paul B Myrdal; James A Warneke; Janine G Einspahr; Hubert G Bartels; Michael Yozwiak; Yira Bermudez; Chengcheng Hu; Peter Bartels; David S Alberts Journal: Cancer Prev Res (Phila) Date: 2015-12-28
Authors: V Kakkassery; K U Loeffler; M Sand; K R Koch; A M Lentzsch; A C Nick; I A Adamietz; L M Heindl Journal: Ophthalmologe Date: 2017-03 Impact factor: 1.059
Authors: Melody J Eide; Richard Krajenta; Dayna Johnson; Jordan J Long; Gordon Jacobsen; Maryam M Asgari; Henry W Lim; Christine C Johnson Journal: Am J Epidemiol Date: 2009-12-06 Impact factor: 4.897
Authors: Alexander H Fischer; Timothy S Wang; Gayane Yenokyan; Sewon Kang; Anna L Chien Journal: J Am Acad Dermatol Date: 2016-05-16 Impact factor: 11.527